期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 81, 期 2, 页码 222-227出版社
WILEY
DOI: 10.1038/sj.clpt.6100040
关键词
-
资金
- NCRR NIH HHS [M01 RR05096, 5M01 RR00044] Funding Source: Medline
- NIAID NIH HHS [IU01AI3844, AI38858, AI27664, UO1 AI27658, U01 AI38855] Funding Source: Medline
- NICHD NIH HHS [N01-HD-3-3345] Funding Source: Medline
We conducted an open-label, steady-state pharmacokinetic (PK) study of drug interactions among HIV-infected women treated with depo-medroxyprogesterone acetate (DMPA) while on nucleoside analogues plus nelfinavir (N = 21), efavirenz (N = 17), or nevirapine (N = 16); or nucleosides only or no antiretroviral therapy as a control group (N = 16). PK parameters were estimated using non-compartmental analysis, with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of ARV PKs before and 4 weeks after DMPA dosing. Plasma progesterone levels were measured at baseline and at 2, 4, 6, 8, 10, and 12 weeks after DMPA dosing. There were no significant changes in MPA area under the concentration curve, peak or trough concentrations, or apparent clearance in the nelfinavir, efavirenz, or nevirapine groups compared to the control group. Minor changes in nelfinavir and nevirapine drug exposure were seen after DMPA, but were not considered clinically significant. Suppression of ovulation was maintained.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据